摘要
目的应用心肌肌钙蛋白I(cTnI)评价瑞芬太尼预处理对非体外偱环冠脉搭桥(OPCAB)患者的心肌保护作用。方法选择24例行OPCAB的冠心病患者,随机分为瑞芬太尼预处理组(R组)和对照组(C组)。所有患者术前口服安定10mg,肌肉注射吗啡10mg、东莨菪碱0.3mg,全麻诱导静脉注射咪唑安定0.08mg/kg,依托咪酯0.1~0.3mg/kg,芬太尼5~10μg/kg,罗库溴铵1mg/kg诱导,吸入1MAC异氟醚,持续静脉输注异丙酚0.8~2μg/ml;间断给予芬太尼5~10μg/kg,哌库溴铵0.05mg/kg。R组:瑞芬太尼5μg/kg溶于50ml生理盐水,于麻醉诱导后10min恒速泵完。C组:泵注同等容量生理盐水。测定术前、术毕及术后1、6、24、48h血浆cTnI水平。结果各组内术后cTnI水平均明显增高(P<0.05)。R组术后cTnI水平显著低于C组(P<0.05)。结论瑞芬太尼预处理可降低OPCAB患者的cTnI水平,减轻心肌损伤。
Objective To investigate the value of cardiac troponin I (cTnI) levels in assessing myocardial protection by remifentanil precondition against myocardial injury induced by off-pump coronary artery bypass (OPCAB). Methods Twenty-four patients undergoing OPCAB were randomized into control and remifentanil preconditioning group (n=12). All the patients received pretreatment with oral diazepam (10 mg), intramuscular morphine (10 mg) and hyosine (0.3 mg). General anesthesia was induced with midazolam (0.08 mg/kg...
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2009年第8期1554-1556,共3页
Journal of Southern Medical University
基金
广东省科技计划项目(2007B030704005
2007B031500002)
